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CLINICAL GUIDELINESThe 2014 American Heart Association/American College
of Cardiology guideline for the management of patients
with valvular heart disease: A changing landscapeRobert C. Neely, MD, Marzia Leacche, MD, Igor Gosev, MD, Tsuyoshi Kaneko, MD,
John G. Byrne, MD, FACC, and Michael J. Davidson, MDThe American Heart Association (AHA) and American
College of Cardiology (ACC) have updated the practice
guidelines for the treatment of patients with valvular heart
disease (VHD).1 The writing committee and task force
members were experts in all aspects of valvular disease
and included representatives from the Society of Cardio-
vascular Anesthesiologists, Society for Cardiovascular
Angiography and Interventions, American Society of Echo-
cardiography, and surgical representatives from The Amer-
ican Association for Thoracic Surgery and Society of
Thoracic Surgery (STS). Importantly, the writing commit-
tee members were free of industry affiliations.
The original AHA/ACC VHD guidelines were released
in 1998, revised in 2006, and updated in 2008.2 The recent
growth in therapeutic options for VHD requires the incorpo-
ration of evolving techniques and current evidence to deter-
mine best practice. With the expansion of transcatheter and
minimally invasive valve surgery, the question is not simply
should we intervene, but how and when. To outline concom-
itant nonsurgical therapeutic advances, the Task Force
coined the phrase guideline-directed medical therapy ‘‘to
represent optimal medical therapy as defined by [the]
ACC/AHA guideline (primarily class I)–recommended
therapies.’’1 Thus, the current guidelines reflect updates in
medical and surgical advances, with new sections summari-
zing the role of transcatheter aortic valve replacement
(TAVR) and transcatheter approaches for the mitral valve.
Evolving approaches for aortic aneurysms and valve type
choices are also discussed.
For severe aortic stenosis, surgical AVR remains a class
I, level of evidence A, recommendation for low or inter-
mediate surgical risk candidates meeting the criteria for
valve replacement. Drawing from several large, multi-
institutional, randomized controlled trials, the guidelines
state that ‘‘TAVR is recommended in patients who meet
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than 12 months’’ (class I, level of evidence B).1 In the
modern era, patients must be risk stratified by comorbid-
ities, procedure complexity, and frailty measures to deter-
mine which intervention, if any, is most appropriate. In
addition to the traditional STS predicted risk of mortality,
frailty estimates have been incorporated to reflect the
spectrum of a patient’s preoperative functional status: no
frailty, able to perform 1 activity of daily living and
perform a 5-m walk in<6 seconds; mild degree of frailty,
unable to perform 1 activity of daily living and perform a
5-m walk in<6 seconds; and moderate-to-severe degree of
frailty, unable to perform 2 activities of daily living.1
Candidates suitable for TAVR must be within 1 of 2
categories:
High-risk—STS predicted risk of mortality>8% or 2
indexes of frailty or>2 organ systems compromised
or possible procedure-specific impediment (eg,
severely atherosclerotic aorta or a hazardous redo
sternotomy with a previous left internal mammary ar-
tery conduit crossing the sternum).
Prohibitive risk—predicted risk with surgery or major
comorbidity>50% at 1 year or>3 organ systems
compromised or severe procedure-specific impedi-
ments (eg, severe atherosclerotic aorta, chest malfor-
mations, previous radiotherapy, or previous bypass
graft adherent to the sternum).
The Placement of Aortic Transcatheter Valve study
demonstrated that among patients deemed at prohibitive
risk, TAVR does not appear to benefit those with an STS
score of 15% (hazard ratio, 0.77; 95% confidence inter-
val, 0.46-1.28; P ¼ .31).3 The Task Force summarized
that a ‘‘poor outcome after TAVR is associated with
advanced age, frailty, smoking or chronic obstructive pul-
monary disease, pulmonary hypertension, liver disease,
prior stroke, anemia, and other systemic conditions.
TAVR is not recommended in patients with (1) [a] life ex-
pectancy of<1 year, even with a successful procedure,
and (2) those with a chance of ‘survival with benefit’ of
<25% at 2 years.’’1 The role of a ‘‘heart valve team,’’ there-
fore, is essential in the evaluation of high-risk surgical can-
didates. Heart valve Centers of Excellence and designated
teams of specialists provide expertise for complex VHD.
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of cardiologists, cardiac surgeons, imaging specialists, and
other dedicated providers will facilitate a comprehensive
patient evaluation and offer expertise in all treatment mo-
dalities not available in most hospitals.
We anticipate more information to emerge about the use
of TAVR for intermediate-risk candidates. Several studies
are ongoing, and, at the time of this writing (May 2014),
the evidence is not sufficient to support a change in the
guidelines for this population. As this information becomes
available and as more data emerge on second- and third-
generation devices, the recommendations for the use of
TAVR are certain to evolve.
The 2014 guidelines are the first to delineate a role for
transcatheter approaches for the mitral valve: ‘‘Transcath-
eter mitral valve repair may be considered for severely
symptomatic patients (NYHA [New York Heart Associa-
tion] class III to IV) with chronic severe primaryMR [mitral
regurgitation] who have favorable anatomy for the repair
procedure and a reasonable life expectancy but who have
a prohibitive surgical risk because of severe co-
morbidities and remain severely symptomatic despite
optimal GDMT [guideline-directed medical therapy] for
[heart failure]’’ (class IIB, level of evidence B). To date,
only 1 randomized control trial has compared surgical
mitral repair and percutaneous mitral valve repair (Mitra-
Clip, Abbott Vascular, Santa Clara, Calif).4 The percuta-
neous repair group had a greater incidence of residual
mitral regurgitation but demonstrated decreased mitral
regurgitation severity, favorable left ventricle remodeling,
and improved symptoms. Proper patient selection remains
essential and should be performed by a multidisciplinary
team, with repair only considered for chronic, primary
mitral regurgitation with New York Heart Association class
III or IV heart failure symptoms.
In addition to transcatheter techniques, the current guide-
lines update the size recommendations for aortic aneurysm
intervention in the setting of a bicuspid aortic valve. Previ-
ous guidelines recommended surgery for ascending aorta
dilatation at any level>5.0 cm for patients with a bicuspid
aortic valve, regardless of valve function. The evidence for
such treatment has largely been anecdotal and limited to 2
large, long-term retrospective cohort studies of patients
with bicuspid aortic valves.5,6 In 1 of these studies, which
followed up 416 patients for a mean of 16 years, the
incidence of aortic dissection was low and estimated at
3.1 cases/10,000 patient-years (95% confidence interval,
0.5-9.5).6 Thus, surgery is recommended for aortic dilata-
tion of 5.1 to 5.5 cm only if the patient has a family history
of aortic dissection or rapid progression of dilatation (0.5
cm/y). For patients with a bicuspid aortic valve and severe
aortic stenosis or regurgitation who are undergoing aortic
valve surgery, the threshold for concomitant ascending
aorta replacement remains 4.5 cm. For all other6 The Journal of Thoracic and Cardiovascular Surgercircumstances, an operation is indicated for more severe
dilatation (>5.5 cm). These measurements apply to the level
of the aortic sinus or any level along the ascending aorta and
should not be adjusted for body size.
Finally, the AHA/ACC task force emphasized that patient
choice regarding the type of valve prosthesis should be
tailored to the individual’s lifestyle and decided after an
in-depth discussion among patient, surgeon, and cardiolo-
gist: ‘‘specifically, the tradeoff between the risk of reopera-
tion for bioprosthetic valve degeneration and the risk
associated with long-term anticoagulation should be dis-
cussed in detail.’’1 At the patient’s request, with current ev-
idence, it is reasonable to proceed with a bioprosthetic valve
at any age. This is especially true with the potential for sub-
sequent transcatheter valve-in-valve implantation for pa-
tients who choose a biologic aortic valve. In contrast, for
patients without a contraindication for anticoagulation
who are considering a mechanical prosthesis, the guidelines
have lowered the recommendation for the age cutoff from
65 years to 60 years for both aortic and mitral valve
replacement.1
The authors of the guidelines have attempted to develop
guidelines to address the clinical circumstances for most pa-
tients. Ultimately, appropriate therapy must be tailored to
the individual patient and directed by providers working
within their area of expertise. With the myriad technolog-
ical advances since the last published guidelines, it is
reasonable to expect continued growth in the field of
VHD, with regional heart valve Centers of Excellence play-
ing an ever increasing role. Amultidisciplinary approach by
experts will help determine when to adhere to these guide-
lines and when a patient-centered departure is appropriate
amid this changing landscape of VHD.
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